GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Monday, May 30, 2022 at 8:30 a.m. - 9:30 a.m. (1ST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call. GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, May 27, 2022, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2022 and to consider and recommend dividend, if any, on Equity shares for the year ended March 31, 2022. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31, 2022 to May 29, 2022 (both days inclusive) for the purpose of approval of Audited Financial Results for the Quarter and year ended March 31, 2022. GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for The Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2022 And To Consider And Recommend Dividend, If Any, On Equity Shares For The Year Ended March 31, 2022.
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 ,inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2022 and to consider and recommend dividend, if any, on Equity shares for the year ended March 31, 2022. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31, 2022 to May 29, 2022 (both days inclusive) for the purpose of approval of Audited Financial Results for the Quarter and year ended March 31, 2022. GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Glenmark Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here GLENMARK PHARMACEUTICALS LTD. - 532296 - Result Of Postal Ballot & Scrutinizer''s Report
Further to our letter dated 13th April, 2022 regarding notice of Postal Ballot, please find enclosed herewith the following - 1. Voting Result as required under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and 2. Scrutinizer''s Report dated 14 May, 2022. Based on the Scrutinizer''s Report, we wish to inform you that the Ordinary Resolutions mentioned in the said Postal Ballot notice have been passed by the members of the Company with requisite majority. The voting result along with the Scrutinizer''s Report is also made available on the Company''s website at www.glenmarkpharma.com. You are requested to take the same on record . GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Of Buyback By Glenmark Pharmaceuticals Limited (The "Company") In Respect Of The US$ 200,000,000 2.00% Resettable Onward Starting Equity-Linked Securities Due 2022 (The "FCC Bonds")
Intimation of buyback by Glenmark Pharmaceuticals Limited (the "Company") in respect of the US$ 200,000,000 2.00% Resettable Onward Starting Equity-Linked Securities due 2022 (the "FCC Bonds")
Glenmark gets tentative nod from USFDA for generic psoriasis foam
Glenmark Pharmaceuticals on Monday said its US-based arm has received tentative approval from the US health regulator for its generic Calcipotriene and Betamethasone Dipropionate foam used to treat psoriasis. The tentative approval granted to Glenmark Pharmaceuticals Inc, USA (Glenmark) by the US Food & Drug Administration (USFDA) is for Calcipotriene and Betamethasone Dipropionate foam of strength 0.005 per cent/0.064 per cent, the company said in a statement. It is the generic equivalent of Leo Pharma AS' Enstilar foam, it added. Citing IQVIATM sales data for the 12 months ended March 2022, the company said Enstilar foam, 0.005 per cent/0.064 per cent achieved annual sales of approximately USD 115.2 million. Glenmark said its current portfolio consists of 174 products authorised for distribution in the US marketplace and 48 abbreviated new drug applications (ANDAs) are pending approval with the USFDA. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%/0.064% GLENMARK PHARMACEUTICALS LTD. - 532296 - Glenmark Receives The ''India Pharma Innovation Of The Year'' Award From The Government Of India
Glenmark receives the ''India Pharma Innovation of the Year'' Award from the Government of India GLENMARK PHARMACEUTICALS LTD. - 532296 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayGLENMARK PHARMACEUTICALS LTD. 2CINL24299MH1977PLC019982 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Harish Kuber Designation: Company Secretary & Compliance Officer EmailId: complianceofficer@glenmarkpharma.com Name of the Chief Financial Officer: VS Mani Designation: Executive Director & Global CFO EmailId: complianceofficer@glenmarkpharma.com Date: 26/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.